Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF V600E MAP2K1 Y130C |
| Therapy | Cetuximab + Dabrafenib |
| Indication/Tumor Type | colorectal cancer |
| Response Type | resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF V600E MAP2K1 Y130C | colorectal cancer | resistant | Cetuximab + Dabrafenib | Preclinical - Cell culture | Actionable | In a preclinical study, Tafinlar (dabrafenib) and Erbitux (cetuximab) combination treatment inhibited senescence in a colorectal cancer cell line harboring BRAF V600E and expressing MAP2K1 Y130C in culture (PMID: 39424923). | 39424923 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (39424923) | Base editing screens define the genetic landscape of cancer drug resistance mechanisms. | Full reference... |